|
Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma
RECRUITINGPhase 2/3Sponsored by West China Hospital
Actively Recruiting
PhasePhase 2/3
SponsorWest China Hospital
Started2025-05-02
Est. completion2026-06-30
Eligibility
Age1 Month – 4 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06798363
Summary
The main objective of this study was to determine the efficacy of different doses of propranolol in the treatment of ulcerattion infantile hemangioma (IH).
Eligibility
Age: 1 Month – 4 YearsHealthy volunteers accepted
Inclusion Criteria: 1. all patients with ulcer IH; 2. children with ulcer IH treated with propranolol. Exclusion Criteria: 1\) children with ulcer IH who received other therapeutic interventions were excluded; 2) Children whose families refused to participate in the study; 3) patients with contraindications to oral propranolol, such as allergy to propranolol, severe bradycardia and bronchial asthma; 4) children lost to follow-up during oral propranolol treatment; 5) children unable to oral propranolol or continue to oral propranolol due to other reasons. \-
Conditions2
CancerInfantile Hemangioma
Interventions1
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2/3
SponsorWest China Hospital
Started2025-05-02
Est. completion2026-06-30
Eligibility
Age1 Month – 4 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06798363